ROIV · Roivant Sciences Ltd.

Roivant Sciences reported preliminary financial and operational updates for the period ending March 31, 2026. The company disclosed a robust liquidity position with approximately $4.3 billion in unaudited consolidated cash, cash equivalents, and marketable securities. During the quarter, Roivant actively returned capital to shareholders, repurchasing nearly 4 million common shares for an aggregate price of approximately $109.7 million, excluding fees and commissions. This financial stability provides a strong backdrop for the company's advancing clinical pipeline.

On the operational front, Roivant announced a significant expansion of the brepocitinib development program. Priovant, a subsidiary, has initiated a seamless Phase 2b/3 potentially registrational trial for brepocitinib in lichen planopilaris (LPP), a morbid inflammatory scalp disorder with no FDA-approved therapies. The first subjects were enrolled in March 2026. This marks the fourth indication in late-stage development for brepocitinib, alongside dermatomyositis (DM), non-infectious uveitis (NIU), and cutaneous sarcoidosis (CS). Notably, the FDA recently granted Priority Review to the NDA for DM, assigning a PDUFA date in the third quarter of 2026.

Conversely, the announcement contained negative topline results from Immunovant’s two Phase 3 clinical studies evaluating batoclimab in thyroid eye disease (TED). The studies failed to meet the pre-specified primary endpoint of ≥2mm proptosis responder rate at Week 24. While safety results were consistent with previous findings, the efficacy failure represents a setback for the program. Immunovant stated it would review future development plans for batoclimab with its partner HanAll Biopharma and remains focused on advancing IMVT-1402, another FcRn blocker, with topline data in Graves’ disease expected in 2027.